Articles related to DRUG EFFICACY

Low-dose (Z)-endoxifen significantly reduced mammographic breast density in premenopausal women while producing fewer treatment-related symptoms than expected with standard tamoxifen exposure. The phase II findings suggest a potential new prevention strategy, but effects on actual breast cancer incidence remain unknown.

A phase 2b trial found that biweekly bofanglutide significantly reduced HbA1c levels and produced weight loss in adults with type 2 diabetes. The findings add to ongoing development of longer-interval GLP-1 therapies, though larger and longer studies remain necessary.

The FDA approved enlicitide, the first oral PCSK9 inhibitor, after phase 3 studies demonstrated substantial LDL-C reductions in patients requiring additional lipid lowering. Cardiovascular outcomes data remain pending.

A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.

A randomized noninferiority trial found that oral fosfomycin matched continued intravenous therapy in stabilized patients with ESBL complicated UTIs after 3 to 7 days of initial IV treatment.

A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.